Biohaven Pharma (BHVN) Misses Q4 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall Street indexes fall more than 1%, hit by tech, Iran war worries
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil prices jump after Trump threatens to hit Iran 'very hard'
- Oracle reports earnings today: Analysts say this metric could 'catalyze higher multiples'
- UBS sees generational semiconductor boom, highlights stock winners
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
- Wall Street indexes fall more than 1%, hit by tech, Iran war worries
- UBS sees generational semiconductor boom, highlights stock winners
Biohaven Pharmaceutical Holding (BHVN) PT Lowered to $63 at Jefferies
March 5, 2025 5:21 AM ESTJefferies analyst Amy Li lowered the price target on Biohaven Pharmaceutical Holding (NYSE: BHVN) to $63.00 (from $64.00) while maintaining a Buy rating.
The analyst comments "BHVN provided program updates during Q4 earnings. Our thoughts - BHV-1300: While we see +'ves in data (~80% median... More
